Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Citizen’s Group Opposes Emergency Approval for Shionogi’s COVID Pill
June 21, 2022
- It’s Time to Revise G1 Withdrawal Scheme, Rule Likely to Be Applied to Only a Few Products: FPMAJ
June 14, 2022
- TRIPS Waiver Discussions Threaten Global Health Security: JPMA, IFPMA
June 13, 2022
- FPMAJ Urges More Precise Handling of CEA Price Tweaks for Products with “Cost Increase” Profile
June 13, 2022
- 4-Year Grace Period Was Good News, but More Should Be Done for Re-Pricing Exclusion: FPMAJ
June 13, 2022
- FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
- FPMAJ Drug Pricing Chief Renews Call for Fundamental Review of Off-Year Re-Pricing
June 10, 2022
- Takata Pharma President Hiroki Takada Becomes New JGA Chief
June 1, 2022
- FPMAJ Chief Vows to Go on Offensive in Pricing Debate, Flags Japan’s Decline in Global Market
May 30, 2022
- JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
May 25, 2022
- JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
May 24, 2022
- PhRMA Hails Launch of Indo-Pacific Economic Framework
May 24, 2022
- INES-Led Coalition Calls for Patient/Citizen Participation in Healthcare Policymaking
May 23, 2022
- Japan, US, European Pharma Groups Prod Price Maintenance of Patented Drugs in Joint Pitch towards Honebuto
May 17, 2022
- PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
May 17, 2022
- JPMA Takes Issue with WTO IP Waiver Proposal for COVID Vaccines
May 13, 2022
- Lagevrio Given to 87,000 via Pharmacies, Paxlovid to 120 as of April 15
May 9, 2022
- FPMAJ Official Prods Rethink of Off-Year Price Revision as Ukraine War Pushes Up Costs
April 27, 2022
- JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
April 27, 2022
- JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
April 25, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…